激素耐药及复发免疫性血小板减少症的治疗进展  

Advances in the Treatment of Glucocorticoid Resistance and Relapsed Immune Thrombocytopenia——Review

作　　者：潘惠敏 文瑞婷 杨志刚 PAN Hui-Min;WEN Rui-Ting;YANG Zhi-Gang(Department of Hematology,Zhanjiang Central Hospital,Guangdong Medical University,Zhanjiang 524045,Guangdong Province,China)

机构地区：[1]广东医科大学附属湛江中心医院血液内科,广东湛江524045

出　　处：《中国实验血液学杂志》2023年第2期616-620,共5页Journal of Experimental Hematology

摘　　要：免疫性血小板减少症(ITP)是一种免疫介导的获得性出血性自身免疫性疾病。目前ITP的一线治疗药物包括糖皮质激素和静脉免疫球蛋白,然而约1/3的患者对一线治疗无反应或激素减量、停药后复发。近几年,随着对ITP发病机制研究的逐渐深入,针对不同发病机理的药物不断涌现,包括免疫调节剂、去甲基化药物、脾酪氨酸激酶(SYK)抑制剂和新生儿Fc受体(FcRn)拮抗剂等,但这些药物大多处于临床试验阶段。本文就目前国内外关于激素耐药及复发ITP治疗的最新研究进展作一综述,为激素耐药及复发ITP的临床治疗提供参考。Immune thrombocytopenia(ITP)is an immune-mediated acquired hemorrhagic autoimmune disease.At present,the first-line therapeutic drugs for ITP include glucocorticoids and intravenous immunoglobulins.However,about 1/3 of the patients had no response to the first-line treatment,or relapsed after dose reduction or withdrawal of glucocorticoids.In recent years,with the gradual deepening of the understanding on the pathogenesis of ITP,the drugs targeting different pathogenesis continually emerge,including immunomodulators,demethylating agents,spleen tyrosine kinase(SYK)inhibitors and neonatal Fc receptor(FcRn)antagonist.However,most of these drugs are in clinical trials.This review summarized briefly the recent advances in the treatment of glucocorticoids resistance and relapsed ITP,so as to provide reference for the clinical treatments.

关 键 词：免疫性血小板减少症 复发难治 免疫调节剂 去甲基化药物 

分 类 号：R558.2[医药卫生—血液循环系统疾病]